BIOPHAUSIA AB
BioPhausia is a Swedish specialty pharma company. BioPhausia focuses on marketing and sales of own products, licensed products and parallel-imported products. The portfolio includes strong brands such as Novalucol, Citodon and Mollipect.
BIOPHAUSIA AB
Social Links:
Industry:
Biotechnology Medical Pharmaceutical
Founded:
1994-01-01
Address:
Stockholm, Stockholms Lan, Sweden
Country:
Sweden
Website Url:
http://www.biophausia.se
Total Employee:
101+
Status:
Active
Contact:
(468)407-6430
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Apache Wordpress Plugins Sitelinks Search Box Yoast WordPress SEO Plugin
Similar Organizations
Uriach
Uriach is a pharmaceutical company specialized in health and wellbeing.
Official Site Inspections
http://www.biophausia.se
- Host name: redirect.portsit.se
- IP address: 193.14.90.203
- Location: Sweden
- Latitude: 59.3247
- Longitude: 18.056
- Timezone: Europe/Stockholm
More informations about "Biophausia AB" on Search Engine
Biophausia AB - Crunchbase Company Profile & Funding
Operating Status Closed. Company Type For Profit. Phone Number (468)407-6430. BioPhausia is a Swedish specialty pharma company. BioPhausia focuses on marketing and sales of own products, licensed products and parallel-imported products. The portfolio includes strong brands such as Novalucol, Citodon and Mollipect.See details»
Medivir divests its pharmaceutical company BioPhausia (Nordic …
Nov 1, 2016 Our commercial organization provides a portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm, Mid Cap. Medivir divests its pharmaceutical company BioPhausia (Nordic Brands) to Karo Pharma.See details»
Medivir Sells Nordic Brands to Karo Pharma
Nov 1, 2016 BioPhausia AB (Nordic Brands) consists of 13 established pharmaceutical drugs with strong brand namesSee details»
BioPhausia AB - Company Profile and News - Bloomberg Markets
BioPhausia AB is a pharmaceutical research and marketing company. The Company specializes in micro-circulation, macromolecules and biopolymers.See details»
Medivir Divests Its Pharmaceutical Company BioPhausia to Karo …
Nov 1, 2016 Medivir today announces that the company has entered into an agreement with Karo Pharma regarding the sale of Medivir’s subsidiary BioPhausia AB (Nordic Brands) to Karo Pharma.See details»
BioPhausia AB: Drug pipelines, Patents, Clinical trials - Synapse
Explore BioPhausia AB with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, and 1 literature, Drug:BP-04.See details»
Medivir completes the divestment of BioPhausia – a transfer of …
Dec 15, 2016 Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces today that the divestment of BioPhausia AB to Karo Pharma AB has been completed.See details»
Karo Pharma acquires BioPhausia - Nordic Life Science
Nov 2, 2016 The transaction entails a divestment of 100 per cent of the shares in Medivir’s wholly owned subsidiary BioPhausia AB for a purchase price of SEK 908 million on a cash and debt free basis including normalized working capital.See details»
Medivir Subsidiary BioPhausia AB Sells Generics Business
Aug 26, 2011 Medivir reports that on 25 August, BioPhausia AB reached an agreement to sell its generics business in the form of subsidiary BMM Pharma AB to Bluefish Pharmaceuticals AB for SEK 26 m plus...See details»
Medivir Divests Its Pharmaceutical Company BioPhausia (Nordic …
Nov 1, 2016 In a structured process of evaluating a sale versus a separate listing, the Board of Directors of Medivir has concluded that a divestment of BioPhausia AB to Karo Pharma is the best alternative for BioPhausia, Medivir and its …See details»
Karo Pharma AB (OM:KARO) completed the acquisition of Biophausia AB ...
Dec 14, 2016 Karo Pharma AB (publ) (OM:KARO) entered into an agreement to acquire Biophausia AB from Medivir AB (OM:MVIR B) for approximately SEK 910 million in cash on November 1, 2016. Under the terms, the purchase price is on a cash and debt free basis, including a normalized working capital.See details»
Medivir acquires Biophausia AB - 2011-04-12 - Crunchbase
Apr 12, 2011 Overview. Acquired Organization: Biophausia AB Biophausia AB is a pharmaceutical company, develops and sells prescription medicines in the Nordic region. Acquiring Organization: Medivir Medivir is a research-based pharmaceutical company with a research focus on oncology and infectious diseases. Announced Date Apr 12, 2011.See details»
BioPhausia AB - Stockholm, Sweden - bionity.com
Apr 12, 2011 Contact. About BioPhausia. BioPhausia is a Specialty Pharma company in the Nordic area. The company provides cost-effective pharmaceuticals and focuses on three fields: generic products, niche products and original drugs. BioPhausia focuses on marketing and sales. BioPhausia has no research program at the present time. Facts …See details»
Medivir divests its pharmaceutical company BioPhausia
Nov 1, 2016 BioPhausia consists of thirteen established pharmaceutical drugs with strong. brand names. For the period of Q3-2015 to Q2-2016, BioPhausia generated revenues. of SEK 189 million. Transaction...See details»
BP-04 - Drug Targets, Indications, Patents - Synapse
3 days ago Basic Info. Drug Type. Small molecule drug. Synonyms. Target - Mechanism - Therapeutic Areas. Neoplasms. Active Indication - Inactive Indication. Solid tumor. Originator Organization. BioPhausia AB. Active Organization - Inactive Organization. BioPhausia AB. Drug Highest Phase Pending Discovery. First Approval Date - …See details»
BioPhausia an innovative Swedish pharmaceutical company …
Company presentation Wednesday morning. BioPhausia is a research intensive speciality drug company with core competence in microcirculation, macromolecules and biopolymers. The company is in tune with an innovative distribution network in Europe. The focus for BioPhausia is to bring drugs from phase I-III onto the market.See details»
Biophausia AB - Crunchbase
Biophausia AB is a pharmaceutical company, develops and sells prescription medicines in the Nordic region.See details»
The Team - Palette Life Sciences
As the Chief Commercial Officer, Travis leads the developmental efforts of the organization by transforming proprietary innovations in medical technology into commercially viable solutions. ... At BioPhausia AB she held positions in business development, sales and marketing. board of directors. David R. Amerson. Chairman of the Board,See details»
BioPhausia AB | VentureRadar
BioPhausia AB VentureRadar profile. Find out more about BioPhausia AB including the VentureRadar Innovation and Growth scores, Similar Companies and more.See details»
Biophausia - Cision News
Proposed candidates for BioPhausia Board In consultation with the existing Board of Directors, a group consisting of Per-Johan Björnstedt, portfolio manager in Skandia AB, and Stellan Lind, President of BioPhausia through February 1, 1999, has prepared the following proposed list of Board candidates for presentation to shareholders at the Company's …See details»